Tag Archives: AZN

Healthcare Sector Roundup: Cardium Therapeutics (NYSE:CXM), Rigel Pharmaceuticals (NASDAQ:RIGL) – CXM, RIGL, AZN, RIGL, AMRN, PFE

Posted on April 6, 2013 by Thomas Vedder

Healthcare sector finished in red land on Friday trading session and sector plunged -0.58%. If we consider key percentage decliners so Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) and Amarin Corporation plc (ADR) (NASDAQ:AMRN) were key stocks while most active stock was Pfizer …

Posted in Healthcare, Latest Headlines | Tagged Amarin, AMRN, AstraZeneca, AZN, Cardium Therapeutics, CXM, NASDAQ:AMRN, NASDAQ:RIGL, NYSE:AZN, NYSE:CXM, NYSE:PFE, PFE, Pfizer, Rigel Pharmaceuticals, RIGL | Comments Off

Bristol Myers Squibb (NYSE:BMY) Fiscal Q4 Profit Outshines Wall Street Forecasts – BMY, PFE, ABT, ABBV, ARIA, BSX, ARNA, AZN, MRK

Posted on January 24, 2013 by Geoff Noir

Bristol Myers Squibb Co (NYSE:BMY) on Thursday announced fiscal Q4 earnings that surpassed analysts’ forecasts after taking a tax benefit for a hepatitis C medicine that failed previous year.

The New York-based drug manufacturer announced in a statement that net …

Posted in Healthcare, Latest Headlines | Tagged Abbott Laboratories, ABBV, AbbVie, ABT, Arena Pharmaceuticals, ARIA, Ariad Pharmaceuticals, ARNA, AstraZeneca, AZN, BMY, Boston Scientific, Bristol-Myers Squibb, BSX, Merck, MRK, NASDAQ:ARIA, NASDAQ:ARNA, NYSE:ABBV, NYSE:ABT, NYSE:AZN, NYSE:BMY, NYSE:BSX, NYSE:MRK, NYSE:PFE, PFE, Pfizer | Comments Off

Abbott Laboratories (NYSE:ABT) Completes Spinoff; AbbVie (ABBV) Operates as Separate Company

Posted on January 3, 2013 by Geoff Noir

Abbott Park, Illinois based Abbott Laboratories (NYSE:ABT) finished the spinoff of its pharmaceutical unit on Wednesday, establishing AbbVie Inc (NYSE:ABBV) as a separate corporation focused on biopharmaceuticals and new medicine development.

Both the companies will continue to share their headquarters …

Posted in Healthcare, Main Post | Tagged Abbott Laboratories, ABT, AstraZeneca, AZN, BIIB, Biogen Idec, JNJ, Johnson, NASDAQ:BIIB, NYSE:ABT, NYSE:AZN, NYSE:JNJ | Comments Off

Bristol Myers Squibb (NYSE:BMY), Pfizer’s (PFE) Eliquis Wins FDA Approval – BMY, PFE, AZN, SNY

Posted on December 31, 2012 by Thomas Vedder

Bristol Myers Squibb Co (NYSE:BMY) and Pfizer Inc (NYSE:PFE), world’s biggest drug maker, reported on Friday that the United States Food and Drug Administration has approved their anti-clotting medicine Eliquis to shatter risks of stroke and blood clots in patients …

Posted in Latest Headlines, Services | Tagged AstraZeneca, AZN, BMY, Bristol-Myers Squibb, NYSE:AZN, NYSE:BMY, NYSE:PFE, NYSE:SNY, PFE, Pfizer, Sanofi, SNY | Comments Off

Eli Lilly (NYSE:LLY) Hikes after Positive Results of Cancer Drug – LLY, SNY, PFE, AZN

Posted on October 16, 2012 by Geoff Noir

Eli Lilly & Co’s (NYSE:LLY) experimental stomach cancer medicine assisted patients with complex disease live longer, found in a study. Shares of the company moved up after the report.

The Indianapolis-based Eli Lilly reported in a statement on Monday that …

Posted in Healthcare, Latest Headlines | Tagged AstraZeneca, AZN, Eli Lilly, LLY, NYSE:AZN, NYSE:LLY, NYSE:PFE, NYSE:SNY, PFE, Pfizer, Sanofi, SNY | Comments Off

Bristol Myers Squibb (NYSE:BMY) Books Impairment Charge of $1.8 Billion in Q3 – BMY, PFE, AZN, SNY

Posted on August 27, 2012 by Geoff Noir

Bristol Myers Squibb Co (NYSE:BMY) will record an impairment charge of $1.8 billion in the third-quarter from its discarded development of a tentative medicine for hepatitis C.

The drug maker reported on late Thursday that it had stopped up development …

Posted in Healthcare, Latest Headlines | Tagged AstraZeneca, AZN, BMY, Bristol-Myers Squibb, NYSE:AZN, NYSE:BMY, NYSE:PFE, NYSE:SNY, PFE, Pfizer, Sanofi, SNY | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.